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Folate-Cyclodextrin Conjugate for Targeted Chemotherapy
Zlata Tofzikovskaya, Orla Howe, Mary McNamara, and Christine O’Connor.
School of Chemical and Pharmaceutical Sciences, DIT Kevin Street, Dublin 8 Ireland and  Materials Synthesis and Applications (MSA)
Research Group, FOCAS Institute, DIT Camden Row DIT Kevin Street, Dublin 8, Ireland. E-mail: ztofzikovsky@dit.ie
A general disadvantage of chemotherapy is that the drugs cannot discriminate between fast-growing cancer cells and normal healthy cells which causes many side effects 
such as hair loss. An ideal solution to current methods of chemotherapy would be the development of a carrier for an anticancer drug which would be able to transport the drug 
and therefore target only cancer cells and release the drug molecules inside the cells. In this work folic acid (FA) is attached to an aminoalkane derivative of β-Cyclodextrin
(CDEn) with a view to developing novel drug delivery systems for therapeutic purposes. Cytotoxisity of folate-conjugate (CDEnFA) is tested on folate over-expressing cell line 
(HeLa cells) and folate receptor deficient cell line (A549 cells). EC50 values compared to standard (Cisplatin).
Introduction
Folate receptors are highly expressed in a range of solid tumor including breast and prostate cancer1. The reported frequency of folate receptors overexpression to other 
cancer cells is 40-80%1. Folate receptor overexpression is an important factor in anticancer targeting development. Many researchers worldwide suggest that  the 
introduction of a substance that has a high affinity to folate receptors  to an anticancer agent would increase drug selectivity and hence lead to a decrease of common side 
effects associated with chemoterapy2. Several drug conjugates are currently used in clinical cancer treatment, and more are in the pipeline for clinical development2. Many 
of them are a combination of folic acid and an anticancer agent. In this work Folic acid was covalently bonded to a cyclodextrin derivative (CDEn) via a peptide bond to 
give a Folate-CDEn conjugate. Once the conjugate was prepared and characterized its toxicity needed to be tested. Number of cytotoxicity tests for accurate assay are 
available. These assays depend on the cell death mechanism3. MTT (3-(4,5-dimethylthylthiazole-2-yl)-2,5-diphenyltetrazoli umbromide) is a widely used method to assay 
cell vialibility.  The MTT substance is reduced by mitochondrial dehydrogenases in living cells to a blue-mageta coloured formazan precipitate. The absorbance of 
dissolved formazan in the visible region correlates with the number of  intact active cell3.  Cytotoxic compounds such as cisplatin are able to damage and destroy cells, 
and thus decrease the reduction of MTT to formazan. Using MTT assay the toxicity of CDEnFA was determined and expressed as an EC50 value which was compared 
with the EC50 value of cisplatin.
Abstract
Materials and Method
The CDEn was prepared from β-Cyclodextrin as reported in Potter at al 5 .The Folate
conjugate has been prepared by the reaction of folic acid with CDEn in pyridine as seen in 
Figure 1 below
A lung cancer cell A549 and breast cancer HeLa cells were cultured in Mega CellTM RPMI-
1640 suplplemented with  penecillin G (100U/ml), L-glutamine, and 15%  fetal calf serum at 
37ºC in incubator containing 5% CO2. Cisplatin 5mM stock solution was prepared in 10% 
NaCl. CDEnFA 5mM stock solution was prepared in DMSO. Cells were seeded at density of 
2000 cells per well of 96-well plates in 100µL medium. After 24 h drugs ( 0.5 – 50 µM) were 
introduced for 24h and 96 h of drug exposure.
Results
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Table 1- EC50 values of different drugs in A549 and HeLa cells(µM)a ± SD
305.95±26.14
360.43±114
HeLa 24h
0.9±0.05
215.15±24.50
A549 96h
3.20±0.482
3604±1658
106.49±10.44
1215.55±658
Cisplatin
CDEnFA
HeLa 96hA549 24h
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Figure 2- Effect of cisplatin(0.5-50µM) and CDEnFA(0.5-50µM) on the 
viability of (A),(B) A549 cell line and (C),(D) HeLa cell line
Conclusion
aEC50 value correspond to the concentration (µM) of the compound 
necessary to reduce activity of to 50% 
Figure 1- synthesis of CDEnFA conjugate
A CDenFA conjugate for potential delivery of antitumor argent has been obtained employing 
DCC-NHS peptide bond formation. The reaction includes formation of the intermediate active 
ester (the product condensation of the carboxyl group and N-hydroxysuccinimide) that further 
reacts with the amine function to yield an amide bond. MTT assay was employed to determine 
whether CDEnFA conjugate has any toxicity effect on chosen tumour cells. Results were 
obtained and expressed in form of EC50 values. This also refers to the concentration of a drug, 
antibody or toxicant that induces a response halfway between the baseline and maximum after 
some time of exposure. In this study the toxicity of Cisplatin (0.5-50µM) was also found and 
used as standard. Percentage of violability of A549 and HeLa cell line presented in Figure2 (B), 
and (D) respectively. According to calculated EC50 values (Table 1) cisplatin has three times 
greater toxicity for HeLa cell line than for A549. These results agree favourably with Li Bai et al1
who reported EC50 of cisplatin (74h exposure) to be 0.7 µM  and Giuliano Ciarimboli et al4 who 
reported EC50 of cisplatin (24h exposure) to be 100.4µM. 
Results obtained for CDEnFA conjugate can be seen in Figure 2 A549cell line (A), and HeLa 
cell line (C). Calculated EC50 values (listed in Table 1) suggest that conjugate itself has no
toxicity effect for A549 or HeLa tumour cell. In both cases EC50 values were nearly ten times 
higher than those for cisplatin.
Discussion
Preliminary investigations suggest that the formation of peptide bond in CDEnFA
conjugate was successful. Conjugates main function is to deliver anticancer agent specifically
to cancer cells. The conjugate was tested in Vitro using MTT assay. Obtained EC50 values
suggest relatively low toxicity when compared to cisplatin ( ten times lower).
1 Li Bai, Rong Zhu, Zhihong Chen, Lei Gao, Potential role of short hairpin 
RNA targeting epidermal growth factor receptor in growth and sensitivity to
drugs of human lung adenocarcinoma cells, J of Biochem.Pharm. 71,8, 1265-1271 (2006)
2 Bioconjugate Chem., 2002, 13 (6), pp 1253–1258
3 Engin Ulukaya, Ferda Ozdikicioglub, Arzu Yilmaztepe Oral,and Meral Demirci, The MTT 
assay yields a relatively lower result of growth inhibition than the ATP assay depending on
the chemotherapeutic drugs tested,J of  Tox. in Vitro, 22, 1 232-239 (2008)
4 Giuliano Ciarimboli, Thomas Ludwig , Detlef Lang, Hermann Pavenstädt, 
Hermann Koepsell , Hans-Jürgen Piechota , Jörg Haier, Ulrich Jaehde||,
Jochen Zisowsky|| and Eberhard Schlatter, Cisplatin Nephrotoxicity Is Critically Mediated
via the Human Organic Cation Transporter 2, American Journal of Pathology.
167 1477-1484 (2005) 
5 Potter, C.F, Metallo-cyclodextrin complexes for the separation of chiral materials,
synthetis and characterisation (2007) Doctoral.
References
